Guardant Health, Inc. (NASDAQ:GH) CEO Sells $3,899,656.77 in Stock

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 77,853 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $50.09, for a total transaction of $3,899,656.77. Following the sale, the chief executive officer now directly owns 2,069,456 shares in the company, valued at $103,659,051.04. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The stock was sold at an average price of $50.07, for a total transaction of $1,990,332.57.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The stock was sold at an average price of $50.00, for a total transaction of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84.

Guardant Health Stock Performance

NASDAQ:GH traded down $0.01 during mid-day trading on Thursday, reaching $49.02. 1,250,531 shares of the company's stock were exchanged, compared to its average volume of 2,124,938. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $52.92. The firm has a market capitalization of $6.07 billion, a PE ratio of -13.77 and a beta of 1.37. The business's fifty day simple moving average is $43.53 and its two-hundred day simple moving average is $41.45.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same period last year, the firm earned ($0.46) earnings per share. Guardant Health's revenue for the quarter was up 20.8% compared to the same quarter last year. As a group, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Ratings Changes

GH has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. UBS Group upped their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Stifel Nicolaus increased their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. TD Securities increased their price objective on shares of Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Finally, Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. Twenty research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $53.29.

Institutional Investors Weigh In On Guardant Health

Large investors have recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in Guardant Health during the fourth quarter worth about $43,000. SVB Wealth LLC acquired a new stake in Guardant Health during the first quarter worth about $54,000. Kimelman & Baird LLC acquired a new stake in Guardant Health during the fourth quarter worth about $58,000. NewEdge Advisors LLC grew its stake in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health during the fourth quarter worth about $61,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.